Anti-LCN6/ LCN5/ UNQ643 functional antibody

Anti-LCN6/ LCN5/ UNQ643 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LCN6/LCN6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1062-Ab-1/ GM-Tg-hg-SE1062-Ab-2Anti-Human LCN6 monoclonal antibodyHuman
GM-Tg-rg-SE1062-Ab-1/ GM-Tg-rg-SE1062-Ab-2Anti-Rat LCN6 monoclonal antibodyRat
GM-Tg-mg-SE1062-Ab-1/ GM-Tg-mg-SE1062-Ab-2Anti-Mouse LCN6 monoclonal antibodyMouse
GM-Tg-cynog-SE1062-Ab-1/ GM-Tg-cynog-SE1062-Ab-2Anti-Cynomolgus/ Rhesus macaque LCN6 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1062-Ab-1/ GM-Tg-felg-SE1062-Ab-2Anti-Feline LCN6 monoclonal antibodyFeline
GM-Tg-cang-SE1062-Ab-1/ GM-Tg-cang-SE1062-Ab-2Anti-Canine LCN6 monoclonal antibodyCanine
GM-Tg-bovg-SE1062-Ab-1/ GM-Tg-bovg-SE1062-Ab-2Anti-Bovine LCN6 monoclonal antibodyBovine
GM-Tg-equg-SE1062-Ab-1/ GM-Tg-equg-SE1062-Ab-2Anti-Equine LCN6 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1062-Ab-1/ GM-Tg-hg-SE1062-Ab-2; GM-Tg-rg-SE1062-Ab-1/ GM-Tg-rg-SE1062-Ab-2;
GM-Tg-mg-SE1062-Ab-1/ GM-Tg-mg-SE1062-Ab-2; GM-Tg-cynog-SE1062-Ab-1/ GM-Tg-cynog-SE1062-Ab-2;
GM-Tg-felg-SE1062-Ab-1/ GM-Tg-felg-SE1062-Ab-2; GM-Tg-cang-SE1062-Ab-1/ GM-Tg-cang-SE1062-Ab-2;
GM-Tg-bovg-SE1062-Ab-1/ GM-Tg-bovg-SE1062-Ab-2; GM-Tg-equg-SE1062-Ab-1/ GM-Tg-equg-SE1062-Ab-2
Products NameAnti-LCN6 monoclonal antibody
Formatmab
Target NameLCN6
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LCN6 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1062-Ag-1Recombinant multi-species LCN6/ LCN5/ UNQ643 protein


    Target information

    Target IDGM-SE1062
    Target NameLCN6
    Gene ID158062,620709,414138,574148,491247,123381514,618665,100068193
    Gene Symbol and Synonyms9230101D24Rik,hLcn5,LCN5,LCN6,UNQ643
    Uniprot AccessionP62502,P62503
    Uniprot Entry NameLCN6_HUMAN,LCN6_MACMU
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000267206
    Target ClassificationN/A

    The target: LCN6, gene name: LCN6, also named as LCN5, UNQ643, hLcn5. Predicted to enable small molecule binding activity. Predicted to be involved in single fertilization. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.